Senate report questions safety of rosiglitazone
Links shared publicly online about this topic.
- 1,362total visits
Senate report questions safety of rosiglitazone
View full resource at endocrinetoday.com
Tags: Diabetes, Diabetes Type 2 Medication, Diabetes Medication, Drug, Avandia, Avandamet, Avandaryl
Most Recently Shared on February 22, 2010 at 10:15 pm By:
Senate report questions safety of diabetes drug rosiglitazone http://ow.ly/1a5D2
FDA will consider halting TIDE, based on advisory committee's input
theheart.org — “Responding to a report issued by the Senate Finance Committee, FDA commissioner Margaret Hamburg says the agency is convening a joint advisory committee meeting to get expert opinion on all the recent evidence questioning rosiglitazone's cardiovascular safety profile—if need be, the agency could stop the much-debated TIDE trial.” View full resource at theheart.org
Most Recently Shared on July 14, 2010 at 1:20 pm By:
#Avandia IoM's Steve Goodman and Ruth Faden present their take on ethics of a trial like TIDE, something FDA asked for. http://bit.ly/cE7Pp3
Waiting for answers on TIDE
theheart.org — “The FDA's response to a Senate investigation of rosiglitazone has led to new speculation about the likelihood that the head-to-head TIDE trial will continue and just what would be lost or gained if it were halted. Also alluded to in Commissioner Hamburg's letter are questions of whether patients in the trial have been made well aware of the safety concerns. Not everyone agrees.” View full resource at theheart.org
Most Recently Shared on July 13, 2010 at 7:44 pm By:
#Avandia - Graham is discussing informed consent in TIDE. An issue heartwire covered in depth: http://bit.ly/dl63Zm
Waiting for answers on TIDE
theheart.org — “The FDA's response to a Senate investigation of rosiglitazone has led to new speculation about the likelihood that the head-to-head TIDE trial will continue and just what would be lost or gained if it were halted. Also alluded to in Commissioner Hamburg's letter are questions of whether patients in the trial have been made well aware of the safety concerns. Not everyone agrees.” View full resource at theheart.org
Most Recently Shared on April 22, 2010 at 7:40 pm By:
Churning over TIDE: Experts mull informed consent and repercussions of potential halt: The FDA's response to a Sen... http://bit.ly/deqvAi
FDA will consider halting TIDE, based on advisory committee's input
theheart.org — “Responding to a report issued by the Senate Finance Committee, FDA commissioner Margaret Hamburg says the agency is convening a joint advisory committee meeting to get expert opinion on all the recent evidence questioning rosiglitazone's cardiovascular safety profile—if need be, the agency could stop the much-debated TIDE trial.” View full resource at theheart.org
Most Recently Shared on April 19, 2010 at 9:00 pm By:
FDA responds to Senate concerns over rosiglitazone; will "reassess" TIDE trial: Responding to a report issued by t... http://bit.ly/b7InFl
Avandia safety, the new Senate report, and the need for outcome based research | CurrentMedicine.tv
currentmedicine.tv — “February 20, 2010 The U.S. Senate just released a 350-page report on the GlaxoSmithKline (GSK) drug Avandia (rosiglitazone). The report investigates” View full resource at currentmedicine.tv
Most Recently Shared on February 27, 2010 at 12:54 pm By:
Healthcare Channel Health Site
Avandia safety, the new Senate report, and the need for outcome based research http://tinyurl.com/yklhooa
Statement From The American Heart Association Following Senate Report On Avandia
procto-med.com — “The US Senate Finance Committee has released a report, which followed a two-year inquiry into the safety of the diabetes drug Avandia (rosiglitazone), and the” View full resource at procto-med.com
Most Recently Shared on February 24, 2010 at 8:40 am By:
Tammi Jacobs Health Professional
Statement From The American Heart Association Following Senate ... http://bit.ly/aXXzPr
Statement From The American Heart Association Following Senate Report On Avandia
mnt.to — “The US Senate Finance Committee has released a report, which followed a two-year inquiry into the safety of the diabetes drug Avandia (rosiglitazone), and the possibility of an increased incidence” View full resource at mnt.to
Most Recently Shared on February 24, 2010 at 2:28 am By:
MedicalNewsToday: Statement From The American Heart Association Following Senate Report On: http://bit.ly/90cK9c Full http://bit.ly/9khAeg
GSK, FDA under fire in new senate report on Avandia
theheart.org — “A new Senate report has rekindled debate about the cardiovascular safety of GlaxoSmithKline's diabetes agent rosiglitazone, stating that there are” View full resource at theheart.org
Most Recently Shared on February 22, 2010 at 2:05 pm By:
New senate report puts Avandia safety in spotlight again: A new senate report has rekindled debate about the cardi... http://bit.ly/90v8fn
Advertisement
